PP2A/B55α substrate recruitment as defined by the retinoblastoma-related protein p107
- Temple University Lewis Katz School of Medicine, United States
- Fox Chase Cancer Center, United States
- University of Arizona, United States
- Hitchcock Medical Center at Dartmouth, United States
- UConn Health, United States
Abstract
Protein phosphorylation is a reversible post-translation modification essential in cell signaling. This study addresses a long-standing question as to how the most abundant serine/threonine Protein Phosphatase 2 (PP2A) holoenzyme, PP2A/B55α, specifically recognizes substrates and presents them to the enzyme active site. Here, we show how the PP2A regulatory subunit B55α recruits p107, a pRB-related tumor suppressor and B55α substrate. Using molecular and cellular approaches, we identified a conserved region 1 (R1, residues 615-626) encompassing the strongest p107 binding site. This enabled us to identify an 'HxRVxxV619-625' short linear motif (SLiM) in p107 as necessary for B55α binding and dephosphorylation of the proximal pSer-615 in vitro and in cells. Numerous B55α/PP2A substrates, including TAU, contain a related SLiM C-terminal from a proximal phosphosite, 'p[ST]-P-x(4,10)-[RK]-V-x-x-[VI]-R'. Mutation of conserved SLiM residues in TAU dramatically inhibits dephosphorylation by PP2A/B55α, validating its generality. A data-guided computational model details the interaction of residues from the conserved p107 SLiM, the B55α groove, and phosphosite presentation. Altogether these data provide key insights into PP2A/B55α mechanisms of substrate recruitment and active site engagement, and also facilitate identification and validation of new substrates, a key step towards understanding PP2A/B55α role in multiple cellular processes.
Data availability
Raw MS data for the the data depicted in Figure 6B are available at MassIVEhttps://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=9c21e08f6a524d7097e8bd45f0d2f375PXD028612.All NMR chemical shifts (Figure 1E-F) have been deposited in the BioMagResBank (BMRB: 28091).Source code folder (PeptideDock_sourceCode) for Figure 7 is a C# project, including retrieval of peptide structures from PDB and other sources such as PISCES, and calculation of distances and data analyses. https://github.com/DunbrackLab/PP2A_PeptideDock.All other data generated or analysed during this study are included in the manuscript and supporting files. Source Data files have been provided.
Article and author information
Author details
Arminja N Kettenbach
Funding
National Institute of General Medical Sciences (R01 GM117437)
- Xavier Graña
National Cancer Institute (R03 CA216134-01)
- Xavier Graña
WW Smith charitable Trust Award (no reference number)
- Xavier Graña
National Cancer Institute (P30 CA006927)
- Roland L Dunbrack Jr.
- Xavier Graña
National Cancer Institute (U54 CA221704)
- Holly Fowle
- Ziran Zhao
National Institute of General Medical Sciences (R01GM134683)
- Wolfgang Peti
National Institute of Neurological Disorders and Stroke (R01NS091336)
- Wolfgang Peti
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- William C Hahn, Dana-Farber Cancer Institute, United States
Publication history
- Received: September 17, 2020
- Preprint posted: March 3, 2021 (view preprint)
- Accepted: October 17, 2021
- Accepted Manuscript published: October 18, 2021 (version 1)
- Version of Record published: November 8, 2021 (version 2)
- Version of Record updated: June 28, 2022 (version 3)
Copyright
© 2021, Fowle et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,452
- Page views
-
- 226
- Downloads
-
- 7
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
PP2A/B55α substrate recruitment as defined by the retinoblastoma-related protein p107
eLife 10:e63181.
https://doi.org/10.7554/eLife.63181
Further reading
-
- Biochemistry and Chemical Biology
Ciliopathies manifest from sensory abnormalities to syndromic disorders with multi-organ pathologies, with retinal degeneration a highly penetrant phenotype. Photoreceptor cell death is a major cause of incurable blindness in retinal ciliopathies. To identify drug candidates to maintain photoreceptor survival, we performed an unbiased, high-throughput screening of over 6,000 bioactive small molecules using retinal organoids differentiated from induced pluripotent stem cells (iPSC) of rd16 mouse, which is a model of Leber congenital amaurosis (LCA) type 10 caused by mutations in the cilia-centrosomal gene CEP290. We identified five non-toxic positive hits, including the lead molecule reserpine, which maintained photoreceptor development and survival in rd16 organoids. Reserpine also improved photoreceptors in retinal organoids derived from induced pluripotent stem cells of LCA10 patients and in rd16 mouse retina in vivo. Reserpine-treated patient organoids revealed modulation of signaling pathways related to cell survival/death, metabolism, and proteostasis. Further investigation uncovered dysregulation of autophagy associated with compromised primary cilium biogenesis in patient organoids and rd16 mouse retina. Reserpine partially restored the balance between autophagy and the ubiquitin-proteasome system at least in part by increasing the cargo adaptor p62, resulting in improved primary cilium assembly. Our study identifies effective drug candidates in preclinical studies of CEP290 retinal ciliopathies through cross-species drug discovery using iPSC-derived organoids, highlights the impact of proteostasis in the pathogenesis of ciliopathies, and provides new insights for treatments of retinal neurodegeneration.
-
- Biochemistry and Chemical Biology
Mutations within Ras proteins represent major drivers in human cancer. In this study, we report the structure-based design, synthesis, as well as biochemical and cellular evaluation of nucleotide-based covalent inhibitors for KRasG13C, an important oncogenic mutant of Ras that has not been successfully addressed in the past. Mass spectrometry experiments and kinetic studies reveal promising molecular properties of these covalent inhibitors, and X-ray crystallographic analysis has yielded the first reported crystal structures of KRasG13C covalently locked with these GDP analogues. Importantly, KRasG13C covalently modified with these inhibitors can no longer undergo SOS-catalysed nucleotide exchange. As a final proof-of-concept, we show that in contrast to KRasG13C, the covalently locked protein is unable to induce oncogenic signalling in cells, further highlighting the possibility of using nucleotide-based inhibitors with covalent warheads in KRasG13C-driven cancer.
